C
Celcuity D
D
CELC
13.710
USD
-0.29
(-2.07%)
قبل الجلسة
حجم التداول
3,428
الربح لكل سهم
-4
العائد الربحي
-
P/E
-5
حجم السوق
519,147,768
العنوان: Celcuity
القطاع: Healthcare
الصناعة: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.